Related references
Note: Only part of the references are listed.Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy
Filip Baert et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Progress in Pharmacogenomics: Bridging the Gap From Research to Practice
I. Cascorbi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease
Ana Gutierrez et al.
GUT (2014)
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial
Laurent Peyrin-Biroulet et al.
GUT (2014)
High-Resolution Melting Curve Analysis for High-Throughput Genotyping of NOD2/CARD15 Mutations and Distribution of These Mutations in Slovenian Inflammatory Bowel Diseases Patients
Mitja Mitrovič et al.
DISEASE MARKERS (2013)
Multidimensional Prognostic Risk Assessment Identifies Association Between IL12B Variation and Surgery in Crohn's Disease
Marla C. Dubinsky et al.
INFLAMMATORY BOWEL DISEASES (2013)
Phenotype-Genotype Profiles in Crohn's Disease Predicted by Genetic Markers in Autophagy-Related Genes (GOIA Study II)
Cecilia Duraes et al.
INFLAMMATORY BOWEL DISEASES (2013)
Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?
C. Reenaers et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study
F. Zorzi et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment
N. Vande Casteele et al.
GUT (2012)
Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE
Robert Lofberg et al.
INFLAMMATORY BOWEL DISEASES (2012)
Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease
Rebecca L. Roberts et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2012)
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease
Luke Jostins et al.
NATURE (2012)
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease
L. S. Kiss et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
Vincent Billioud et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial
Remo Panaccione et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY (2011)
Haplotype in the IBD5 region is associated with refractory Crohn's disease in Slovenian patients and modulates expression of the SLC22A5 gene
Katja Repnik et al.
JOURNAL OF GASTROENTEROLOGY (2011)
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47
Carl A. Anderson et al.
NATURE GENETICS (2011)
Association of caspase-9 and RUNX3 with inflammatory bowel disease
C. Guo et al.
TISSUE ANTIGENS (2011)
Extraintestinal manifestations of inflammatory bowel disease: Epidemiology, diagnosis, and management
Signe Larsen et al.
ANNALS OF MEDICINE (2010)
Clinical Experience with Adalimumab in a Multicenter Swiss Cohort of Patients with Crohn's Disease
Cristina Nichita et al.
DIGESTION (2010)
CTLA4 CT60 Single-Nucleotide Polymorphism Is Associated with Slovenian Inflammatory Bowel Disease Patients and Regulates Expression of CTLA4 Isoforms
Katja Repnik et al.
DNA AND CELL BIOLOGY (2010)
Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease
Filip Baert et al.
GASTROENTEROLOGY (2010)
Genome-wide searching of rare genetic variants in WTCCC data
Tao Feng et al.
HUMAN GENETICS (2010)
Genome Wide Association (GWA) Predictors of Anti-TNFα Therapeutic Responsiveness in Pediatric Inflammatory Bowel Disease
Marla C. Dubinsky et al.
INFLAMMATORY BOWEL DISEASES (2010)
Genome-wide association identifies multiple ulcerative colitis susceptibility loci
Dermot P. B. McGovern et al.
NATURE GENETICS (2010)
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
Andre Franke et al.
NATURE GENETICS (2010)
Diverse Genome-wide Association Studies Associate the IL12/IL23 Pathway with Crohn Disease
Kai Wang et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2009)
Novel Loci, Including Those Related to Crohn Disease, Psoriasis, and Inflammation, Identified in a Genome-Wide Association Study of Fibrinogen in 17 686 Women The Women's Genome Health Study
Jacqueline S. Danik et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2009)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Cytotoxic T lymphocyte antigen-4 promoter-658CT gene polymorphism is associated with ulcerative colitis in Chinese patients
Yan Luo et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2009)
Efficacy of adalimumab for the management of Inflammatory Bowel Disease in the Clinical Setting
Matthew W. Trinder et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2009)
The 5q31 variants associated with psoriasis and Crohn's disease are distinct
Yonghong Li et al.
HUMAN MOLECULAR GENETICS (2008)
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis
Andre Franke et al.
NATURE GENETICS (2008)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Association of DLG5 variants with inflammatory bowel disease in the New Zealand Caucasian population and meta-analysis of the DLG5 R30Q variant
Brian L. Browning et al.
INFLAMMATORY BOWEL DISEASES (2007)
Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric Crohn's disease
Robert N. Baldassano et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility
Miles Parkes et al.
NATURE GENETICS (2007)
Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis
John D. Rioux et al.
NATURE GENETICS (2007)
Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4
Cecile Libioulle et al.
PLOS GENETICS (2007)
A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1
Jochen Hampe et al.
NATURE GENETICS (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study
Edouard I. Louis et al.
PHARMACOGENETICS AND GENOMICS (2006)
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene
Richard H. Duerr et al.
SCIENCE (2006)
The TNF/ADAM 17 system:: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease
Vinciane Dideberg et al.
PHARMACOGENETICS AND GENOMICS (2006)
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
J. Satsangi et al.
GUT (2006)
Oratory markers in IBD: Magic, or unneccessary toys?
S Vermeire et al.
GUT (2006)
Evaluation of short-term responsiveness and cutoff values of Inflammatory Bowl Disease Questionnaire in Crohn's disease
T Hlavaty et al.
INFLAMMATORY BOWEL DISEASES (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease
MM Dring et al.
GASTROENTEROLOGY (2006)
Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease
K Yamazaki et al.
HUMAN MOLECULAR GENETICS (2005)
Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease
T Hlavaty et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease
E Louis et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Tumour necrosis factor-α receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab
M Pierik et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene:: an analysis in 534 patients from two multicenter, prospective GCP-level trials
S Mascheretti et al.
PHARMACOGENETICS (2002)
Inflammatory bowel disease
DK Podolsky
NEW ENGLAND JOURNAL OF MEDICINE (2002)
NOD2/CARD15 does not influence response to infliximab in Crohn's disease
S Vermeire et al.
GASTROENTEROLOGY (2002)
Interleukin-4 and interleukin-4 receptor gene polymorphisms in inflammatory bowel diseases
W Klein et al.
GENES AND IMMUNITY (2001)
Share Paper
